BiotechTube
CoreMedic

CoreMedic

Munich, Germany· Est.
coremedic.de
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $17.5M

Overview

CoreMedic is a private, clinical-stage medical device company pioneering a minimally invasive treatment for mitral valve disease. Its flagship product, the ChordArt TMVr system, aims to replicate surgical chordal replacement via a catheter, positioning it as a potential first-line therapy for patients with severe primary mitral regurgitation. The company has progressed through initial human trials with positive five-year data and is led by a management team with deep experience in cardiovascular device development and commercialization. CoreMedic is currently pre-revenue and working towards making its system available to patients.

Cardiovascular DiseaseStructural Heart Disease

Technology Platform

Catheter-based system for transcatheter mitral valve repair (TMVr) via artificial chordal implantation.

Funding History

2
Total raised:$17.5M
Series A$15M
Seed$2.5M

Opportunities

The large and growing unmet need in mitral regurgitation, especially for a minimally invasive first-line therapy, presents a significant market opportunity.
ChordArt's anatomical repair approach could offer superior durability for primary MR compared to existing edge-to-edge devices, creating a strong product differentiation.
The company's location in a leading European medtech cluster and its experienced team provide a solid foundation for execution.

Risk Factors

The company faces high clinical and regulatory risk, as success depends on positive outcomes in future pivotal trials.
It is pre-revenue and will require substantial additional capital to reach commercialization.
Competition in the transcatheter mitral space is intense from well-funded large-cap medtech firms with established commercial footprints.

Competitive Landscape

CoreMedic competes in the transcatheter mitral valve repair (TMVr) segment, directly challenging Abbott's MitraClip (and its successors), which uses an edge-to-edge repair technique. It also faces future competition from other repair technologies (e.g., annuloplasty devices) and transcatheter mitral valve replacement (TMVR) systems from Edwards, Medtronic, and others. ChordArt's chordal replacement approach is a key differentiator targeting primary MR specifically.

More companies in Drug Delivery & Formulation →More companies in Germany →